Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer

NCT04502602 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Tumor
Ovarian Cancer

Interventions

DRUG: Neratinib 160 mg
DRUG: Neratinib 200 mg
DRUG: Neratinib 240 mg
DRUG: Niraparib 100 mg
DRUG: Niraparib 200 mg
DRUG: Niraparib 300 mg
DRUG: Niraparib at RP2D
DRUG: Neratinib at RP2D

Sponsor

Virginia Commonwealth University

Collaborators

[object Object]
[object Object]